Kymera Therapeutics, Inc. KYMR
We take great care to ensure that the data presented and summarized in this overview for Kymera Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KYMR
View all-
Price T Rowe Associates Inc Baltimore, MD6.86MShares$324 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6.65MShares$314 Million2.94% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.56MShares$310 Million5.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.62MShares$266 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA5.5MShares$260 Million9.44% of portfolio
-
Wellington Management Group LLP Boston, MA5.37MShares$254 Million0.04% of portfolio
-
Atlas Venture Life Science Advisors, LLC4.9MShares$232 Million47.0% of portfolio
-
Black Rock Inc. New York, NY4.16MShares$196 Million0.0% of portfolio
-
Siren, L.L.C. New York, NY3.43MShares$162 Million7.74% of portfolio
-
State Street Corp Boston, MA1.55MShares$73.5 Million0.0% of portfolio
Latest Institutional Activity in KYMR
Top Purchases
Top Sells
About KYMR
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Insider Transactions at KYMR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 17
2025
|
Bruce N. Jacobs Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
79,220
-25.84%
|
$3,961,000
$50.0 P/Share
|
|
Sep 17
2025
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
79,220
+20.53%
|
$158,440
$2.08 P/Share
|
|
Sep 16
2025
|
Nello Mainolfi Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
30,000
-4.34%
|
$1,470,000
$49.0 P/Share
|
|
Sep 16
2025
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+4.16%
|
$60,000
$2.08 P/Share
|
|
Sep 03
2025
|
Brian Adams Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,500
+50.0%
|
-
|
|
Jun 30
2025
|
Bvf Partners L P Director |
BUY
Open market or private purchase
|
Direct |
317,167
+8.02%
|
$13,955,348
$44.0 P/Share
|
|
Jun 30
2025
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
655,500
+9.15%
|
$28,842,000
$44.0 P/Share
|
|
Jun 11
2025
|
Elena Ridloff |
SELL
Open market or private sale
|
Direct |
4,500
-100.0%
|
$225,000
$50.0 P/Share
|
|
Jun 11
2025
|
Elena Ridloff |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+50.0%
|
$90,000
$20.29 P/Share
|
|
Jun 03
2025
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
6,349
-100.0%
|
$311,101
$49.0 P/Share
|
|
Jun 03
2025
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+50.0%
|
$63,490
$10.34 P/Share
|
|
Jun 03
2025
|
Nello Mainolfi Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
30,000
-4.34%
|
$1,470,000
$49.0 P/Share
|
|
Jun 03
2025
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+4.16%
|
$60,000
$2.08 P/Share
|
|
Jun 03
2025
|
Elena Ridloff |
SELL
Open market or private sale
|
Direct |
12,000
-80.0%
|
$552,000
$46.25 P/Share
|
|
Jun 03
2025
|
Elena Ridloff |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+50.0%
|
$324,000
$27.67 P/Share
|
|
Jun 03
2025
|
Pamela Esposito |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$245,000
$49.04 P/Share
|
|
Jun 03
2025
|
Pamela Esposito |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$145,000
$29.55 P/Share
|
|
May 23
2025
|
Jeremy G Chadwick Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,575
-3.73%
|
$74,675
$29.3 P/Share
|
|
Apr 08
2025
|
Noah Goodman Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+49.96%
|
-
|
|
Mar 31
2025
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+9.93%
|
$50,000
$2.08 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 215K shares |
|---|---|
| Open market or private purchase | 973K shares |
| Exercise of conversion of derivative security | 215K shares |
| Open market or private sale | 192K shares |
|---|